source
- Nuvig Therapeutics pauses CIDP trial of NVG-2089, cites enrollment and cost challengesNuvig Therapeutics, backed by major pharmaceutical partners, announced it is stopping development of its lead fusion protein NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy (…
- Secretive new issue links diverse groups, raises concerns for pharma industryThe article, dated October 6, 2026, was written by senior reporter Max Bayer and carries the title “In DC, a secretive new thorn has appeared in pharma’s side.” It notes that the Seattle Latino Ch…